© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Steven K. Wagner
Articles
New task force guideline returns PSA screening to center stage
November 01, 2008
When the U.S. Preventive Services Task Force reported that routine prostate cancer screening for older men appears to result in little benefit, the announcement raised more than a few eyebrows in the urologic medical community.
Move to make CME an out-of-pocket cost gains ground
October 01, 2008
STANFORD, California-In a bid to become free of commercial influence, Stanford University School of Medicine has cut off funding from pharmaceutical and medical device companies for some continuing medical education (CME) programs. As of last month, educational offerings will be held at Stanford facilities rather than resorts and hotels, whenever possible.
Avastin/sunitnib RCC trial closes after serious toxicities
August 01, 2008
The lead investigator in an evaluation of bevacizumab (Avastin) combined with sunitinib malate (Sutent) for renal cell carcinoma (RCC) said the project would be abandoned. FDA issued a product safety alert after Genentech, Avastin’s developer, reported serious complications in several patients enrolled in the phase I trial.